De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PYC Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

PYC Therapeutics heeft een totaal eigen vermogen van A$81.1M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$91.2M en A$10.2M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$66.87m
Aandelen	AU$81.05m
Totaal verplichtingen	AU$10.18m
Totaal activa	AU$91.24m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$85.6M ) PYC } overtreffen de korte termijn passiva ( A$9.1M ).

Langlopende schulden: De kortetermijnactiva PYC ( A$85.6M ) overtreffen de langetermijnschulden ( A$1.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PYC is schuldenvrij.

Schuld verminderen: PYC heeft de afgelopen 5 jaar geen schulden gehad.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PYC heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: PYC heeft voldoende kasruimte voor 1.7 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 33.2 % per jaar.

PYC Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board recently bought AU$81k worth of stock

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy